Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.30 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657400 | 0.81 | ALDH1A1 (0.31) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL4664575 | 0.75 | KMT2A (0.41) | KDM4EALDH1A1GAAHPGDMAPT | |
| SCHEMBL5116642 | 0.75 | GAA (0.43) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL4735946 | 0.74 | ELANE (0.40) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL4664863 | 0.72 | LMNA (0.40) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL4736255 | 0.67 | ALDH1A1 (0.39) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL4739793 | 0.66 | TSHR (0.36) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4739791 | 0.66 | TSHR (0.36) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4664696 | 0.64 | CA12 (0.51) | — | |
| SCHEMBL8832310 | 0.64 | ADORA3 (0.40) | KDM4EALDH1A1GAAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | KDM4E 1927/4885ALDH1A1 293/4885GAA 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.